Other studies suggested that BRAF mutations confer a poorer prognosis on stage II to III colon cancers, but no conclusive prognostic significance for KRAS mutations could be reached among early and medium stage CRCs16–18. The gene discussed is BRAF; the disease is malignant colon neoplasm.